
Maybe going into the office isn't so bad?
24.12.2025 | 6 Min.
2025 has been the year of getting dragged back to the office for plenty of workers — some part-time, but many full-time in the case of big finance and tech corporations. Thing is, in-person work appeals to many younger workers. Today, we'll hear the perspective of one. Then, the State Department says it will deny visas to five European citizens, including a former top EU official, and domestic production is still adjusting to tariffs.

The Trump administration can't withhold disaster relief
24.12.2025 | 6 Min.
A federal judge has ordered the Trump administration to restore Homeland Security funding to 12 states and the District of Columbia. The administration had held back hundreds of millions of dollars from what it called "sanctuary jurisdictions." The cuts affected programs intended to support local police and emergency response in urban areas. Plus, food banks are bracing for strain ahead of changes to SNAP. We hear how services will be impacted on the ground in Kentucky.

China puts the brakes on driverless taxis
24.12.2025 | 8 Min.
From the BBC World Service: Plans to mass-produce and sell self-driving vehicles in China have been delayed after news spread of a crash involving one earlier this year. Chinese regulators gave narrow approval to just two out of nine companies to operate autonomous taxis on highways. We learn more. Then, we hear why 2025 was a mixed picture for commodities. And later, Martha Stewart joins her friend Snoop Dogg as she invests in the U.K. soccer team, Swansea.

Disney and OpenAI and short videos, oh my!
23.12.2025 | 7 Min.
A little over a week ago, Disney became the first major media company to strike a content licensing deal with Sora, OpenAI's short-form video platform. This means that people on Sora can start making videos with Disney characters. Today, we'll chat about what it means for consumers, the companies, and artists in the entertainment industry. But first: GDP growth jumped in the third quarter, and it was not just consumers buying stuff.

A new era for weight-loss drugs
23.12.2025 | 6 Min.
GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.



Marketplace Morning Report